Kell K/k (KEL) Antigen Genotyping
Also known as: KEL GENO
Use
This test is used to determine parental or neonatal Kell (K/k) genotype to assess the risk for alloimmune hemolytic disease. It is particularly important for cases involving erythrocyte alloimmunization which can result in hemolytic transfusion reactions or hemolytic disease of the fetus and newborn (HDFN). The test detects the presence of the Kell blood group antigens, K and k, which are important in transfusion medicine.
Special Instructions
Counseling and informed consent are recommended for genetic testing, and consent forms are available online. This test requires the submission of an Informed Consent for Genetic Testing, which is mandatory for patients from New York. A Patient History Form is available on the ARUP website or by contacting ARUP Client Services.
Limitations
The test does not detect rare nucleotide changes that can lead to altered or partial antigen expression and null phenotypes. Patients who have undergone hematopoietic stem cell transplants may receive inconclusive results. Additionally, abnormal signal intensities might result in indeterminate genotyping results.
FDA ApprovedNew York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 31208-2
- 41096-9
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (K2EDTA), pink (K2EDTA).
Storage Instructions
Refrigerated
Causes for Rejection
Yellow (ACD solution A or B); plasma or serum. Specimens collected in sodium heparin tubes. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient: 72 hours |
| Refrigerated | Refrigerated: 1 week |
| Frozen | Frozen: 1 month |